Figure 7
From: PML is required for telomere stability in non-neoplastic human cells
The expression of the APL fusion protein PML/RARα impairs the telomeric function of PML. (a) Representative image from immuno-FISH experiments with a telomere probe (red, Cy3) and an anti-PML antibody (Alexa488), performed in human CD34+ HPCs infected with a control vector (CTRL) or a PML/RARα expressing vector. An enlargement of a PML/Telomere colocalization detected in CTRL cells is shown. (b) Percentage of cells with the indicated number of PML/telomere colocalization in control or PML/RARα expressing human CD34+ HPCs in a representative experiment of three. 100 cells were analyzed. (c) Percentage of CD34+ human HPCs with the indicated percentage of PML signals colocalizing with telomeres in a representative experiment. In control cells (CTRL) PML-NB were counted. In PML/RARα expressing cells microspeckles were counted. 100 cells were analyzed. One representative experiment of three is shown. (d) Telomere length in murine bone marrow cells obtained between 2 and 4 months after transplant with syngeneic Lin− bone marrow cells, infected in vitro with a control retroviral vector (CTRL) or a PML/RARα expressing vector. Telomeres length is expressed in arbitrary fluorescence units relative to a standard curve. Each dot represents a mouse. A red line indicates the average value: CTRL 29.7±4.6 s.d. PML/RARα 25.8±4.9 s.d. The indicated P-value is based on a two-tailed Student’s t-test.
